← Leaderboards
Richard J Bram
St. Jude Children'S Research Hospital
$12,289,390
Attributed
$12,792,223
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,792,223 · 12
By mechanism
R01$10,861,904 · 8
R61$1,005,666 · 1
R21$380,408 · 1
R56$339,975 · 1
P30$204,270 · 1
Top collaborators
- Steven H Olson1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Stephen X Skapek$24,951,237
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLeadCellsGenesTumorProteinsMolecularMediatingRegulationCessation Of LifeCell SurvivalPlayCyclophilin BCell DeathMouse ModelBiologicalIn VivoBiochemicalApoptosisBaseSignal TransductionPeptidylprolyl IsomeraseIn VitroPhenotype
Grant awards (44)
Cellular senescence in aging and age-related disease.$349,800
R01 · FY2022 · AG · contact PI
Cellular senescence in aging and age-related disease (Supplement application)$159,000
R01 · FY2022 · AG · contact PI
BubRI in Cancer and Aging$398,863
R01 · FY2021 · CA · contact PI
Cellular senescence in aging and age-related disease.$349,800
R01 · FY2021 · AG · contact PI
IGNITE: Development of novel cyclophilin B/PIKfyve inhibitors for treatment of Malignant Peripheral Nerve Sheath Tumors$1,005,666
R61 · FY2020 · NS
Cellular senescence in aging and age-related disease.$349,800
R01 · FY2020 · AG · contact PI
BubRI in Cancer and Aging$221,862
R01 · FY2020 · CA · contact PI
PQ6: Role of Cellular Senescence in Late Effects of Childhood Cancer Therapy$172,913
R21 · FY2018 · CA · contact PI
PQ6: Role of Cellular Senescence in Late Effects of Childhood Cancer Therapy$207,495
R21 · FY2017 · CA · contact PI
High throughput screen for selective inhibitors of cyclophilin B$379,313
R01 · FY2015 · NS · contact PI
Cyclophilin B as a therapeutic target in glioblastoma$344,969
R01 · FY2015 · NS · contact PI
High throughput screen for selective inhibitors of cyclophilin B$392,671
R01 · FY2014 · NS · contact PI
Cyclophilin B as a therapeutic target in glioblastoma$341,518
R01 · FY2014 · NS · contact PI
High throughput screen for selective inhibitors of cyclophilin B$400,363
R01 · FY2013 · NS · contact PI
Cyclophilin B as a therapeutic target in glioblastoma$332,895
R01 · FY2013 · NS · contact PI
Cyclophilin B as a therapeutic target in glioblastoma$344,969
R01 · FY2012 · NS · contact PI
CAML in T cell Development and Function$381,805
R01 · FY2011 · AI · contact PI
Cyclophilin B as a therapeutic target in glioblastoma$344,969
R01 · FY2011 · NS · contact PI
CAML in T cell Development and Function$30,878
R01 · FY2011 · AI · contact PI
CAML in T cell Development and Function$336,575
R01 · FY2010 · AI · contact PI
CAML in T cell Development and Function$339,975
R01 · FY2009 · AI · contact PI
CAML in Normal and Oncogenic Functions of the EGFR$279,026
R01 · FY2009 · CA · contact PI
CAML in T cell Development and Function$339,975
R01 · FY2008 · AI · contact PI
Calcium Modulating Cyclophilin Ligand in Normal & Oncogenic Functions of the EGFR$279,026
R01 · FY2008 · CA · contact PI
CAML in T cell Development and Function$339,975
R56 · FY2007 · AI · contact PI
Calcium Modulating Cyclophilin Ligand in Normal & Oncogenic Functions of the EGFR$279,026
R01 · FY2007 · CA · contact PI
Role of TACI in B Cell Function and Transformation$260,257
R01 · FY2007 · CA · contact PI
CAML in Normal and Oncogenic Functions of the EGFR$287,360
R01 · FY2006 · CA · contact PI
Role of TACI in B Cell Function and Transformation$268,030
R01 · FY2006 · CA · contact PI
CAML in Normal and Oncogenic Functions of the EGFR$294,275
R01 · FY2005 · CA
Role of TACI in B Cell Function and Transformation$274,480
R01 · FY2005 · CA
Role of TACI in B Cell Function and Transformation$274,480
R01 · FY2004 · CA
ROLE OF CADML IN EMBRYONIC AND LYMPHOCYTE DEVELOPMENT$255,948
R01 · FY2004 · CA
Role of TACI in B Cell Function and Transformation$274,480
R01 · FY2003 · CA
ROLE OF CADML IN EMBRYONIC AND LYMPHOCYTE DEVELOPMENT$250,407
R01 · FY2003 · CA
TACI AND B CELL FUNCTION AND TRANSFORMATION$252,487
R01 · FY2002 · CA
ROLE OF CADML IN EMBRYONIC AND LYMPHOCYTE DEVELOPMENT$243,522
R01 · FY2002 · CA
CORE--CELL MICROINJECTION SHARED RESOURCE$0
P30 · FY2002 · CA
TACI AND B CELL FUNCTION AND TRANSFORMATION$245,135
R01 · FY2001 · CA
ROLE OF CADML IN EMBRYONIC AND LYMPHOCYTE DEVELOPMENT$236,427
R01 · FY2001 · CA
CORE--CELL MICROINJECTION SHARED RESOURCE$0
P30 · FY2001 · CA
TACI AND B CELL FUNCTION AND TRANSFORMATION$237,995
R01 · FY2000 · CA
ROLE OF CADML IN EMBRYONIC AND LYMPHOCYTE DEVELOPMENT$229,543
R01 · FY2000 · CA
CORE--CELL MICROINJECTION SHARED RESOURCE$204,270
P30 · FY2000 · CA